Anirban Maitra: Will MPR Still Matter in Pre-Op Pancreatic Cancer Trials?

Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Important question by Brendon Stiles, Gavitt Woodard in Journal of Clinical Oncology with implications beyond Lung Cancer

Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials? How to harmonize end points when comparing chemo vs targeted Rx arms?

For example, in the Pancreatic Cancer neoadjuvant space, MPR has been a great surrogate of outcomes when used in “conventional” pre-op chemoRT trials. Will MPR continue to be pertinent as KRAS inhibitors are used in the pre-op space? Much to learn!”

Title: Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?

Authors: Gavitt A. Woodard, Brendon M. Stiles

Read the Full Article.